Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 805 across all filing types
Latest filing 2017-12-05 Share Issue/Capital Cha…
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
Pharming announces significant conversion of its Ordinary Convertible Bonds
Share Issue/Capital Change Classification · 99% confidence The document is a press release announcing a significant corporate financial event: the conversion of Ordinary Convertible Bonds into new shares and the cashless exercise of warrants. This directly relates to changes in the company's capital structure and financing instruments. This fits the definition of 'Capital/Financing Update' (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER) focusing on operational results, or a general Regulatory Filing (RNS), as it pertains to a specific financing action.
2017-12-05 English
Pharming Submits Supplemental Biologics License Application to FDA for RUCONEST(r) for Prophylaxis of Hereditary Angioedema Attacks
Regulatory Filings Classification · 100% confidence The document is a press release dated November 27, 2017, announcing that Pharming Group N.V. has submitted a supplemental Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for RUCONEST®. This announcement details regulatory action (submission to FDA) concerning a product, which is a form of corporate news release. It is not a full Annual Report (10-K), an Earnings Release (ER), a Call Transcript (CT), or a formal Audit Report (AR). Since it is a specific announcement about a regulatory submission and product development, it fits best under the general category of Regulatory Filings (RNS) as a broad announcement, although it contains significant operational/product news. However, given the context of major regulatory milestones being announced via press release, and lacking a more specific category like 'Regulatory Submission Notice', RNS serves as the most appropriate general regulatory announcement category, as it is not a financial report or management change. It is not short enough to definitively be an RPA based on the 'Menu vs Meal' rule, as it contains substantial background information, but it is a regulatory update announcement.
2017-11-27 English
Pharming Group reports financial results for the first nine months of 2017
Earnings Release Classification · 100% confidence The document explicitly states it presents the "(unaudited) financial report for the first nine months and the third quarter ended 30 September 2017." It contains detailed financial highlights, income statement tables comparing Q3 and 9-month results against the prior year, commentary on financial performance, and an outlook. This structure and content strongly indicate a comprehensive financial report covering a period shorter than a full year (nine months). This aligns perfectly with the definition of an Interim / Quarterly Report (IR). It is not a brief announcement (RPA/ER) because it contains the full financial details and commentary, and it is not the Annual Report (10-K) because the period covered is nine months. 9M 2017
2017-10-26 English
Pharming announces positive data from paediatric clinical trial with RUCONEST®
Earnings Release Classification · 92% confidence The document is a press release dated October 2, 2017, announcing positive data from a clinical trial for the drug RUCONEST® in treating hereditary angioedema (HAE) in children. It details trial design, efficacy, safety, and includes quotes from management and boilerplate forward-looking statements and contact information. This format—a news announcement detailing recent operational or clinical progress—is characteristic of an Earnings Release (ER) or a general press release that doesn't fit a specific financial filing category like 10-K or IR. Since it is announcing clinical trial results, which are key operational updates, it aligns best with the 'Earnings Release' (ER) category, which often includes operational highlights preceding formal financial reports, or it could be classified as a general Regulatory Filing (RNS). Given the content is a substantive announcement of positive clinical data, it is more specific than a generic RNS. However, it is not a comprehensive financial report (10-K or IR) nor a presentation (IP). In the context of corporate communications, press releases announcing significant operational milestones (like positive trial data) are often categorized alongside Earnings Releases (ER) if they are timely announcements of performance indicators, or sometimes as Investor Presentations (IP) if they are highly detailed. Since this is a press release format announcing results, and not a formal financial report, 'ER' (Earnings Release - initial announcement of periodical/key results) is the closest fit for a significant operational update, although 'RNS' (Regulatory Filings) is a strong fallback. Given the nature of the announcement (positive clinical data), it functions as a key operational update, similar to an earnings highlight. I will classify it as ER, as it is a direct announcement of a key performance indicator (clinical success). Q4 2017
2017-10-02 English
Pharming Group N.V. and HAEi International Patient Organization announce partnership with Inceptua Medicines Access for “HAEi Global Access Program”
Regulatory Filings Classification · 95% confidence The document is a press release dated September 22, 2017, announcing a partnership between Pharming Group N.V., HAEi International Patient Organization, and Inceptua Medicines Access regarding a 'HAEi Global Access Program' for the drug RUCONEST®. This type of announcement, detailing strategic business developments, partnerships, and product access programs, is characteristic of a general corporate announcement rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is a press release announcing a significant business event and does not fit into the more specific categories (like M&A, Capital Change, or Director Dealing), it falls best under the general Regulatory Filings/Announcements category, which serves as a fallback for non-standard corporate news releases. Given the context of financial reporting databases, this is often categorized as a Regulatory News Service (RNS) item if a more specific code isn't applicable, or sometimes as a general Investor Relations document. Given the options, RNS is the most appropriate general announcement category for this type of news release that isn't a core financial report or specific corporate action.
2017-09-26 English
Pharming announces conclusion of FDA End of Phase
Regulatory Filings Classification · 99% confidence The document is a press release from Pharming Group N.V. announcing the conclusion of End-of-Phase 2 interactions with the FDA regarding RUCONEST® for HAE prophylaxis and stating the intention to submit a BLA efficacy supplement (sBLA) in Q4. This type of announcement, detailing regulatory progress, clinical trial outcomes, and future submission plans, is characteristic of an Earnings Release (ER) or a general corporate update. Since it focuses on key operational and regulatory milestones rather than a full financial statement (10-K, IR) or a management discussion (MDA), and it is a direct announcement of results/progress, 'ER' (Earnings Release) is the most fitting category for significant operational news, even if it's not strictly quarterly earnings figures. It is a specific operational update, not a general regulatory filing (RNS) or a presentation (IP). Given the context of providing key operational/regulatory updates, ER is appropriate.
2017-09-11 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.